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. Non-small-cell lung cancer (NSCLC), the most common subtype, is associated with frequent mutations in KRAS (∼30%). KRAS is also frequently mutated in other tumor types, including pancreatic (>90%) and colon (∼30%) cancer (2) . Although various pharmacological inhibitors are being developed for RAS, especially for the mutant KRAS G12C (3) (4) (5) , these small molecules have not been tested in the clinic (6, 7) . As a result, advanced oncogenic KRAS lung cancers are usually treated with conventional therapy such as radiation and chemotherapy, often with limited success (1, 8) .
Controlled expression of oncogenic RAS cDNA in mouse models of melanoma, lung, breast, and pancreatic cancer has shown that the withdrawal of oncogenic RAS results in complete tumor regression (9) (10) (11) . This phenomenon, known as "oncogene addiction," suggests that oncogenic KRAS alleles (e.g., KRAS
G12D
) not only initiate tumorigenesis but also play a crucial role in tumor maintenance. To recapitulate KRAS oncogene addiction in a mouse model of lung cancer, we developed a conditional Kras shRNA system (shKras) to knock down Kras in Kras G12D/+ ;p53 −/− (KP) cell lines derived from a mouse lung tumor (12) (13) (14) . When we orthotopically transplanted shKras KP cells into immunocompromised mice, we found that Kras-driven lung tumors can escape oncogene addiction and become independent of Kras signaling (termed Kras independence) (15, 16) .
Because shRNAs targeting Kras do not completely eliminate Kras expression, residual Kras in cells could contribute to Krasindependent tumor growth. The best way to rule out this possibility is to genetically delete Kras altogether. Unfortunately, the Kras knockout mouse is embryonically lethal (17) , and genetic disruption of KRAS-or other oncogenes-in human cells remains a challenge due to the low efficiency of homologous recombination using traditional gene-targeting technology. We recently showed that CRISPR (18) can be used to efficiently and specifically edit cancer genes in adult mice in a fraction of the time and cost of traditional mouse models (19) (20) (21) . CRISPR therefore provides a flexible genetic system to manipulate the function of cancer genes (22, 23) .
Previous work has shown that oncogenic KRAS epigenetically silences Fas expression (24, 25) . In addition, RAS directs epigenetic silencing of Fas through a highly ordered pathway that culminates in methylation of the Fas promoter (26, 27) . It remains unexplored whether Fas can be restored by genetic inactivation of oncogenic RAS.
Significance
Oncogenic KRAS underlies 30-90% of lung, colon, and pancreatic cancers, but despite more than 30 y of research, clinical inhibitors of KRAS-and potential resistance mechanisms-remain elusive. Using CRISPR-mediated genome editing of oncogenic Kras, we show that some lung cancer cells can survive Kras knockout, indicating the existence of mechanisms that allow tumors to escape Kras oncogene addiction. We identify genes highly expressed in Kras knockout cells, including the Fas receptor gene. Antibodies that activate Fas receptor selectively induced apoptosis in Kras-independent lung cancer cells, suggesting a potential strategy for combinatorial therapies against Krasdriven tumors. These findings have direct translational implications for the treatment of lung cancer and other KRAS mutant cancer types. (30) (31) (32) . Lentiviral vector (lentiCRISPR) with puromycin selection marker, as described previously (33) , was used to deliver Cas9 and a sgRNA targeting Kras G12D (sgKras) into the target cells (Fig. 1A) . The puromycinresistant single-cell clones expressing sgKras were screened for Kras elimination and specific indel mutations at target loci. Immunoblot analysis of single clones expressing sgKras, using anti-Kras antibody showed the total absence of endogenous Kras protein (Fig. 1B) . Furthermore, deep-sequencing analysis revealed 2-nt deletions at the G12D allele (Fig. 1C) . Although we designed sgKras to target the G12D sequence (Fig. 1A) , a 1-nt deletion was detected at the wild-type allele (Fig. 1C ). This confirmed that CRISPR can tolerate mismatch between the sgRNA and target site, consistent with known CRISPR off-target effects (34) . These biallelic deletions shift the reading frame of Kras mRNA, likely resulting in premature termination of translation and nonsense-mediated decay of the Kras mRNA, as shown in immunoblots of Fig. 1B . We therefore defined these clones as Kras −/− (Kras knockout) cells. The Kras −/− clones show markedly reduced proliferation and colony-forming ability compared with Kras G12D/+ (Fig. 1D ), further validating the role of Kras in cell proliferation in lung cancer. Nevertheless, Kras −/− cells are viable and form small colonies in an in vitro colony formation assay (Fig. 1D) .
To test whether Kras −/− cells can form tumors in vivo, we transplanted Kras G12D/+ and Kras −/− cells s.c. in immunosuppressed nude mice. Kras −/− cells formed tumors (n = 3 mice), but detection of tumor was much slower (60 d) compared with Kras G12D/+ cells (20 d) (Fig. S1A ). In addition, we observed glandlike structure and more cytoplasm of Kras −/− tumor by H&E staining (Fig. S1B) , providing availability to further investigate Kras −/− tumor pathology. Taken together, these data show that cancer cells derived from oncogenic Kras tumors can indeed escape complete genetic disruption of Kras, and the resulting Krasindependent cancer cells can still form tumors in nude mice.
Transcriptome Analysis of Kras Knockout Cells Revealed Distinct Gene
Signatures. To explore the mechanisms of Kras independence, RNA sequencing (RNA-seq) was performed in Kras . These genes are listed in Dataset S1 ("DEG differentially expressed genes"). We then analyzed whether these differentially expressed genes were enriched in any gene ontology or pathways, using the Gene Set Enrichment Analysis (GSEA) and the Molecular Signature Database (MSigDB) (35) . The 603 up-regulated genes were enriched in many cancerrelated pathways (Fig. 2C ), most notably epithelial to mesenchymal transition (q value = 7.25E-53), YAP (q value = 8.30E-18) as well as sets of genes that are down-regulated upon activation of an oncogenic form of KRAS (q value = 1.08E-29). Conversely, the 216 down-regulated genes are enriched in the sets of genes up-regulated by KRAS activation (q value = 3.27E-9). The entire list of enriched gene sets and pathways are provided in Dataset S1 ("Panther or GSEA"). We further confirmed that mRNA levels of RAS ortholog genes (Hras and Nras) did not change in Kras −/− cells (Fig. 2D ). In addition, the sgKras did not induce indel mutations at Hras and Nras genomic loci ( Fig. S2 A and B) . These data suggest that Hras and Nras do not compensate for the inactivation of oncogenic Kras in this model.
To narrow down the list of differentially expressed genes and identify a possible secondary target in Kras −/− cells, we made the following assumptions: (i) the gene should be up-regulated upon Kras knockout, (ii) the gene should encode a plasma membrane protein, allowing it to be more easily targeted. Out of the 603 up-regulated genes, 189 were annotated as plasma membrane proteins (Dataset S1). To identify up-regulated genes with the most significant P values and largest fold changes, we ranked each of the 189 genes by its average rank of P value. Fold change of the top 10 genes in Kras −/− clones is shown in Fig. 2E . We further analyzed the expression profile of these top 10 candidate genes using The Cancer Genome Atlas (TCGA) datasets (lung adenocarcinoma vs. normal), and found that 7 candidate genes were significantly down-regulated in tumor samples (Fig. S2C ). This analysis indicated that these candidates may have a putative role in development or progression of human lung cancer. Moreover, some of these of the candidates, such as DLC1 (36), FAT4 (37) , and FAS (28) , are well-known tumor suppressors.
Fas Is Up-Regulated in Kras-Independent Cancer Cells. Among the top 10 genes highly expressed in Kras −/− cells from the RNA-seq, we focused to investigate Fas (which encodes the Fas receptor) for two reasons. First, the Fas receptor triggers apoptosis through cellintrinsic pathway (38, 39) , and it has been implicated in various malignancies (28) , hence an attractive therapeutic target. Second, based on previous work (26, 27) , Fas expression has been shown to be regulated by Ras-dependent pathways. Following validation of RNA-seq data, the quantitative RT-PCR (qRT-PCR) and immunoblot analysis in parental Kras G12D/+ and Kras −/− cells revealed that Kras G12D/+ cells expressed very low levels of Fas, whereas Kras −/− cells showed a marked increase in Fas mRNA and protein levels ( Fig. 3 A and B) . Oncogenic RAS activates several downstream signaling pathways, including the MAPK and phosphoinositide 3-kinase (PI3K)/AKT pathways (2). Consistent with previous reports, that Kras-dependent silencing of Fas is partly mediated by MAPK pathway (26), we also observed an increased level of Fas mRNA in Kras G12D/+ cells treated with MEK inhibitor U0126 (Fig. 3C) .
Previous studies have shown that expression of oncogenic RAS in mouse NIH 3T3 cells transcriptionally silenced Fas, thereby preventing Fas ligand-induced apoptosis (25) . Subsequent studies using genome-wide RNAi screens identified cofactors required for RAS-mediated epigenetic silencing of Fas (27) . Kras directs epigenetic silencing of Fas through an ordered pathway that culminates in methylation of the Fas promoter and recruitment of corepressor complex (26, 27) . Because Kras G12D/+ cells expressed relatively lower levels of Fas mRNA, we hypothesized that Fas could be transcriptionally silenced in these cells. The Kras-mediated epigenetic silencing of Fas requires two major events, first is the methylation of promoter by DNA methyltransferase, DNMT1, and then trimethylation of histone H3 at lysine 27 (H3K27me3) catalyzed by the histone methyltransferase Ezh2, a component of polycomb repressive complex 2 (26, 27) . shRNA-mediated knockdown of either Ezh2 or Dnmt1 significantly increased Fas expression in Kras G12D/+ cells, suggesting that both factors mediate Kras-dependent silencing of Fas (Fig. S3A) .
We (Fig. 3 D  and E) . Consistent with previous studies (27) , Dnmt1 and DNA methylation were also significantly enriched at the Fas promoter in Kras G12D/+ cells compared with Kras −/− cells (Fig. 3 F and G) . Thus, the high levels of Fas mRNA in Kras −/− cells is consistent with low levels of Dnmt1 and EZH2 and their corresponding epigenetic marks at the Fas promoter. Moreover, we found that H3K4 acetylation was enriched at the Fas promoter in Kras −/− cells (Fig. S3B) , consistent with its transcriptionally active state. These data indicate that genetic inactivation of oncogenic Kras leads to transcriptional activation and restoration of Fas expression.
Fas-Mediated Apoptosis Can Eliminate Kras-Independent Cells. Because Fas is a major mediator of apoptosis on the cell surface, we hypothesized that activation of Fas might selectively trigger apoptosis of Kras −/− cells. Using fluorescence-activated cell sorting (FACS), we confirmed that the Fas receptor is highly expressed on the surface of Kras −/− cells compared with Kras G12D/+ cells (Fig. 4A) . As reported before, binding of Fas ligand or Fas-activating antibodies to Fas receptor triggers apoptosis through cell-intrinsic pathway (28) . We tested whether a Fas-activating antibody can induce Fas-mediated cell death in Kras −/− cells. When incubating cells with an antibody (Jo2), which binds and activates mouse Fas receptor (28), we observed that many Kras −/− cells became round in shape and detached from the plate, compared with few dead Kras G12D/+ cells (Fig. 4B) . Furthermore, we measured the apoptotic cells by Annexin V staining using FACS and observed that ∼50% of Jo2-treated Kras −/− cells were Annexin V positive compared with ∼5% of Jo2-treated Kras G12D/+ cells (Fig. 4 C and D) , demonstrating that Fas activation can selectively induce apoptosis in Kras −/− cells over the oncogenic Kras G12D/+ cells. These results demonstrated that, in the absence of Kras, Fas expression is significantly restored, conferring sensitivity to Fas antibody-induced apoptosis.
To investigate whether the Fas restoration can be rescued by oncogenic RAS, we reintroduced an oncogenic RAS cDNA in Kras −/− cells. Because Kras −/− cells constitutively expressed Cas9 and Kras sgRNA, these cells are refractory to a Kras G12D cDNA. However, our deep-sequencing data showed that the Hras allele is not affected by the Kras sgRNA. We introduced oncogenic HRAS in Kras −/− cells through retrovirus expressing a HRAS-V12 cDNA (40) . Consistent with our previous results of Fas restoration upon loss of Kras (Fig. 3) , overexpression of HRAS-V12 in Kras −/− cells led to dramatic decrease in Fas mRNAs (Fig. S4A) . Moreover, Fas receptor-mediated apoptosis triggered by the Jo2 antibody was fully rescued in Kras −/− cells expressing HRAS-V12 (Fig.  S4B) . Thus, reintroduction of oncogenic RAS rapidly suppresses Fas expression in nearly all Kras −/− cells. Together, our data suggest Fas activating antibody as a potential therapeutic strategy to kill Kras-independent cancer cells following Kras silencing.
KRAS Knockout Human Cancer Cells Are Sensitive to FAS-Mediated
Apoptosis. To assess whether CRISPR can edit KRAS in human NSCLC cells carrying KRAS mutations, we chose A549 human lung adenocarcinoma cells, which harbor a homozygous KRAS G12S allele (41). Using similar approach as described above, A549 cells were infected with lentivirus expressing Cas9 and a guide RNA that targets human KRAS (sgKRAS). sgKRAS induced genome editing (Fig. S5 ) and significantly reduced total KRAS protein level in a cell population (Fig. 5A) . Concordant with our results in mouse lung cancer cells, we found that some A549 cells survive KRAS knockout. Likewise, we also observed an increase in FAS mRNA (Fig. 5B ) and receptor level (Fig. 5C ) in sgKRASexpressing A549 cells.
To explore methods to overcome resistance to KRAS knockout in human cells, we hypothesized that activation of FAS could also selectively induce apoptosis in KRAS knockout A549 cells. By incubating cells with an activating antibody for human FAS (clone EOS9.1), we observed that KRAS knockout cells are sensitive to FAS-mediated apoptosis (Fig. 5 D-F) . These results indicate a potential strategy to overcome resistance for KRAS inhibition in human NSCLC by activating FAS.
To ensure that the increased sensitivity to FAS activation is indeed a phenotype of CRISPR-mediated KRAS knockout, we used previously reported DLD1 colon cancer cells (KRAS G13D/+ vs. KRAS −/+ ) generated by targeting G13D allele by traditional homologous recombination (42) . As expected, KRAS −/+ DLD1 cells also exhibited increased sensitivity to FAS antibody-induced apoptosis. As shown in Fig. 6 A and B and Fig. S6 , incubation of FAS-activating antibody with KRAS knockout (KRAS −/+ ) DLD1 cells, markedly increased Annexin V-positive apoptotic cells. This suggests that KRAS knockout leading to restored FAS expression is a general phenomenon, and that KRAS silencing confers sensitivity to FAS-induced apoptosis both in lung cancer cells edited by CRISPR and in colon cancer cells generated by traditional homologous recombination. Therefore, this conserved mechanism may provide a therapeutic strategy to suppress tumor relapse alongside future generation of KRAS inhibitors (Fig. 6C) .
A Combination of HDAC Inhibitor and Fas Antibody Induces Apoptosis
in Oncogenic Kras Cells. DNA methylation on CpG motifs in gene promoters is often accompanied by the recruitment of HDACs to the transcriptional regulatory site, thereby altering local chromatin structure and inhibiting transcription. General inhibitors of class I and II HDACs, alone or in combination with the methylation inhibitor 5-azacitydine, or its congener 5-aza-deoxycytidine (5Aza) are being studied in clinical trials for treatment of diverse types of tumors (43) . Furthermore, HDAC inhibitors alone can induce promoter de-methylation and de-repression (44) . Because Krasdirected epigenetic silencing of Fas also requires HDACs (45), we asked whether DNA methylation inhibitors 5Aza or HDAC inhibitors such as Trichostatin A (TSA) or suberoylanilide hydroxamic acid (SAHA) can restore Fas expression in Kras G12D/+ cells. All of these inhibitors significantly increased Fas mRNA expression in Kras G12D/+ mouse lung cancer cells (Fig. 7A) . Furthermore, two pan-HDAC inhibitors TSA and SAHA both significantly up-regulated Fas receptor level on the cell surface (Fig. 7B) . Finally, we observed that TSA or SAHA pretreatment sensitized Kras G12D/+ cells to Fas-mediated apoptosis in combination with Jo2 antibody (Fig. 7 C and D, and Fig. S7 ). These results suggest that exploiting the Fas activation as an Achilles' heel in oncogenic Kras cells using HDAC inhibitors can potentially provide a complementary approach to Kras inhibitors.
Discussion
Herein, we report CRISPR/Cas9-mediated genome editing of Kras in mouse and human lung cancer cells.
CRISPR Can Effectively Model Genetic Deletion of Oncogenes. Traditional technologies have limited ability to model complete silencing of oncogenes because of the low efficiency of homologous recombination without DNA breaks (18, 22) . The CRISPR system is flexible and provides a rapid and facile genetic system to functionally investigate mechanisms of both KRAS and other "undruggable" oncogenes in lung cancer pathology. Using CRISPR to model genetic disruption of oncogenes will pave the road for identifying therapeutic targets (22, 23) .
Cancer Cells Can Escape KRAS Oncogene Addiction and Survive Independent of KRAS. Cancer therapy can be improved by specifically modulating genes in resistance pathways. However, resistance to KRAS-targeted therapy is unknown due to the lack of effective small-molecule inhibitors for KRAS (16) . Our data uncover KRAS independence upon complete KRAS knockout, which is consistent with our previous report that Kras mutant lung tumor can escape from RNAi-mediated Kras knockdown (16) . Although KRAS knockout cells exhibited decreased colony formation ability, these cells are viable, implying mechanisms of resistance to KRAS inhibition or depletion. The recovery of tumors in the absence of Kras activity indicates potential resistance mechanisms to Ras inhibitors. Inhibiting KRAS alone, therefore, might be insufficient for treating KRAS-driven cancer in humans.
RNA-seq revealed a number of differentially expressed genes between oncogenic Kras and Kras knockout cells (Fig. 2) . Understanding additional mechanisms of KRAS independence will be critical for tailoring treatment decisions in future generations of KRAS inhibitors being developed by the RAS initiative at the National Cancer Institute (3) (4) (5) . Moreover, because we used Kras G12D/+ ;p53 −/− mouse lung cancer cells, it remains unclear how additional genetic lesions (e.g., p53
−/− ) contribute to Kras independence. Future work is needed to investigate how Kras independence is affected by various genetic contexts.
Fas as an Achilles' Heel in Kras-Independent Cells. Because KRASindependent cells are selectively sensitive to FAS-mediated apoptosis, understanding how KRAS regulates FAS might unveil treatment targets. Potential therapeutic options (such as siRNA) might exploit these targets to improve the efficacy of KRAS inhibitors. Moreover, a better understanding of the epigenetic regulation of FAS might allow us to turn FAS on and exploit it in other cancer types. Additional studies are also needed to determine whether Fas activation could mediate rejection of Ras-deficient tumor cells during early stages of lung tumor or organ development.
Tumor-Targeted Fas Activation Is Required in Vivo. Our results suggest that a Fas-activating antibody can selectively induce apoptosis in Kras knockout cells. However, normal somatic cells also express Fas receptor. For example, hepatocytes are highly sensitive to FAS-mediated apoptosis; the systemic injection of high-dose Jo2 antibody induces apoptosis in the liver (28) . Thus, FAS-activating antibody needs to be specifically delivered to tumor cells to avoid liver damage. Future studies will explore ways to tackle this challenge together with KRAS silencing. It may also be that endogenous FAS ligand excreted from tumor microenvironment can modulate apoptosis upon KRAS silencing in vivo.
In conclusion, our study has pinpointed FAS activation as a potential strategy to improve the efficacy of future KRAS inhibitors. Because KRAS mutations are prevalent in lung, colon, and pancreatic cancer and are associated with poor patient outcomes, these findings will be critical for developing effective ways to inhibit KRAS and prevent tumor relapse.
Materials and Methods
Vectors and Cloning. sgRNAs targeting mouse Kras G12D or human KRAS were designed using Broad Institute online tool (https://www.broadinstitute.org/ rnai/public/analysis-tools/sgrna-design). The following sgRNA sequences were used: mouse Kras
G12D
, 5′-GTGGTTGGAGCTGATGGCGT-3′, and human KRAS, 5′-GTAGTTGGAGCTGATGGCGT-3′. Oligos were annealed and cloned into the lenti.U6sgRNA.Cas9-2A-Puro vector using a standard BsmBI protocol. WZLHygro (Addgene; 18750) or WZL-HRAS-V12 (40) were gifts from Scott Lowe, Memorial Sloan Kettering Cancer Center, New York.
ChIP Assays. ChIP assays were performed as previously described (26) using DNMT1 (Abcam), EZH2 (CST) and H3K27me3 (Millipore), and H3K4Ac (Abcam) antibodies. ChIP products were analyzed by qRT-PCR using Fas promoter primer sets (Tables S1 and S2) corresponding to transcription start site (TSS) for EZH2, H3K27me3, and ∼1 kb upstream of TSS for DNMT1. Samples were normalized to input DNA, results were analyzed using the ΔΔCt method, and fold enrichment at target site was calculated with respect to IgG control.
Quantitative PCR. Total RNA was purified using an RNeasy Mini Kit (74104; Qiagen). Reverse transcription was performed and diluted cDNA was used as template for real-time PCR. TaqMan probes or SYBG primers were used to measure expression of mouse or human Fas (Tables S1 and S2 ).
Immunoblot Analysis. Cells were harvested and lysed in RIPA buffer with proteinase and phosphatase inhibitors. Cell lysate was quantified and equal amounts of protein were loaded into a 4-12% NuPage Bis-Tris gel (Life Technologies). The proteins isolated by the gel was then transferred to nitrocellulose membrane, blocked with blocking buffer (Odyssey), and then incubated with antibody against KRAS (sc-30; Santa Cruz) and Fas (Upstate; 05-351) overnight at 4°C. An immunofluorescent secondary antibody (LICOR) was used for the Odyssey Imaging machine.
Statistical Analysis. All quantitation data were collected from at least three independent experiments, and the difference between groups were determined using two-tailed Student's t test, with P < 0.05 considered to be significant. All animal study protocols were approved by the University of Massachusetts Institutional Animal Care and Use Committee.
